The Revenue for the quarter ended March 2026 of Rs. 2520.52 millions grew by 22.94 % from Rs. 2050.20 millions.Net Profit witnessed a 158.01% growth almost the double from Rs. 79.75 millions to Rs. 205.76 millions of same quarter last year.OP of the company witnessed a marginal growth to 447.15 millions from 270.23 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	2520.52	2050.20	22.94	9404.75	8198.06	14.72	9404.75	8198.06	14.72
Other Income	-11.96	3.83	-412.27	25.82	36.15	-28.58	25.82	36.15	-28.58
PBIDT	447.15	270.23	65.47	1529.29	1386.03	10.34	1529.29	1386.03	10.34
Interest	94.37	84.00	12.35	366.11	231.12	58.41	366.11	231.12	58.41
PBDT	352.78	186.23	89.43	1163.18	1154.91	0.72	1163.18	1154.91	0.72
Depreciation	76.48	78.43	-2.49	308.32	210.64	46.37	308.32	210.64	46.37
PBT	276.30	107.80	156.31	854.86	944.27	-9.47	854.86	944.27	-9.47
TAX	70.54	28.05	151.48	223.36	244.95	-8.81	223.36	244.95	-8.81
Deferred Tax	24.22	25.12	-3.58	86.34	57.51	50.13	86.34	57.51	50.13
PAT	205.76	79.75	158.01	631.50	699.32	-9.70	631.50	699.32	-9.70
Equity	100.28	100.28	0.00	100.28	100.28	0.00	100.28	100.28	0.00
PBIDTM(%)	17.74	13.18	34.59	16.26	16.91	-3.82	16.26	16.91	-3.82

Gufic Biosciences Ltd.